Paion - Positive prospects with strategic uncertainties
By 5 July 2020, the FDA is due to announce its decision on remimazolam (ByFavo) for procedural sedation (PS). In Japan, Remimazolam (Anerem) was approved in January for general anaesthesia (GA). Paion guides to royalties of under €1m for 2020. In the EU, the possible approval for PS is due in H121. The GA European trial has closed early with 424 patients; this potentially gives launch from late 2021 with top-line data in H220. Paion is considering licensing or acquiring products to make a direct European salesforce economic. Until this happens, we base our valuation on a royalty deal. Due to a reappraisal of short- and longer-term costs, our indicative value is adjusted to €270m, formerly €317m. Paion is funded until H221 and has loan facilities to take cash until 2022 if needed.Paion is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company focusing on developing and commercializing drugs to be used in out-patient and hospital-based anesthesia, sedation and critical care services. Co.'s key compound is Remimazolam, an intravenous ultra short-acting and controllable anesthetic/sedative drug candidate in advanced stages of development for use in procedural sedation and general anesthesia.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.